A look at U.S. Food and Drug Administration PDUFA dates for end-of-August and early-September 2020.

Genentech’s Risdiplam showed significant improvement in motor function in people aged 2-25 who have been diagnosed with Type 2 or 3 spinal muscular atrophy.

Roche company Genentech announced that the Phase III IMvigor010 trial of Tecentriq as a post-surgery monotherapy did not hit the primary endpoint in muscle-invasive urothelial cancer (MIUC).